FGF21 transgenic animals show lower levels of serum insulin, glucose, triglycerides (TG), cholesterol, lower hepatic TG content, improved insulin sensitivity, resistance to diet-induced obesity, and a significantly extended lifespan compared with their wild-type counterparts (35–37). The gene discussed is INS; the disease is Obesity.